跳至主要内容
临床试验/CTRI/2015/02/005491
CTRI/2015/02/005491进行中(未招募)未知

Mobile Short Message Service (SMS) alerts for reducing the toxicity and improving protocol compliance during cancer chemotherapy: A randomized controlled trial - SMS study

Tata Medical Center0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • •Provide informed consent and sign the patient information sheet
  • •- Own a mobile phone with text message (SMS) facility.
  • •- Diagnosed with stomach cancer (all histological types) and are planned for peri-operative chemotherapy (before surgery) with EOX protocol i.e. combination of Epirubicin, Oxaliplatin and Capecitabine given every 3 weeks.
  • •- Diagnosed with colorectal cancer (post-surgery and/or radiotherapy, including metastatic disease) and planned to start on adjuvant or palliative chemotherapy with CapOx protocol i.e. combination of Capecitabine and Oxaliplatin given every 3 weeks.
  • •- Residing within 50km radius of TMC.
  • •- Patient or any of his/her immediate family member(s) who are able to read and comprehend text message in English

排除标准

  • •- Not a citizen of India e.g. patients from neighbouring countries like Bangladesh, Nepal, Bhutan.
  • •- Non-resident Indians i.e. Indians residing outside India but visiting India for cancer treatment

研究者

相似试验